Pregabalin

From Wikipedia, the free encyclopedia

(Redirected from Lyrica)
Jump to: navigation, search
Pregabalin
Systematic (IUPAC) name
(S)-3-(aminomethyl)-5-methylhexanoic acid
Identifiers
CAS number 148553-50-8
ATC code N03AX16
PubChem 5486971
DrugBank APRD01198
Chemical data
Formula C8H17NO2 
Mol. mass 159.23 g.mol-1
Pharmacokinetic data
Bioavailability ≥90%
Protein binding Nil
Metabolism Negligible
Half life 5–6.5 hours
Excretion Renal
Therapeutic considerations
Pregnancy cat.

B3 (Au), C (U.S.)

Legal status

S4 (Au), POM (UK), Schedule V (U.S.)

Routes Oral

Pregabalin (INN) (pronounced /prɨˈgæbəlɨn/) is an anticonvulsant drug used for neuropathic pain, as an adjunct therapy for partial seizures, and in generalized anxiety disorder. It was designed as a more potent successor to gabapentin. Pregabalin is marketed by Pfizer under the trade name Lyrica.

Recent studies have shown that pregabalin is effective at treating chronic pain in disorders such as fibromyalgia[1] and spinal cord injury[2]

It is considered to have a dependence liability if misused, and is classified as a Schedule V drug in the U.S.[3]

Contents

Pregabalin was initially developed by medicinal chemist Richard Bruce Silverman at Northwestern University in the United States. The drug was approved in the European Union in 2004. Pregabalin received U.S. Food and Drug Administration (FDA) approval for use in treating epilepsy, diabetic neuropathy pain and post-herpetic neuralgia pain in June 2005, and appeared on the U.S. market in fall 2005.

Like gabapentin, pregabalin binds to the α2δ subunit of the voltage-dependent calcium channel in the central nervous system. However, the exact mechanism of action is unknown.

Pregabalin is indicated for:

  • Treatment of neuropathic pain in adults
  • Adjunctive therapy in adults with partial seizures with or without secondary generalization
  • Fibromyalgia pain. The FDA has approved Pregabalin as an indicated use on June 21, 2007[4].

Adverse drug reactions associated with the use of pregabalin include:[6][7]

No pharmacokinetic interactions have been demonstrated in vivo. The manufacturer notes some potential pharmacological interactions with oxycodone, lorazepam and ethanol (alcohol). Concurrent use may increase the central nervous system effects of these medications (e.g. drowsiness, effects on concentration).[6]

  1. ^ http://www.prnewswire.com/cgi-bin/stories.pl?ACCT=104&STORY=/www/story/10-25-2002/0001827864&EDATE=
  2. ^ http://www.prnewswire.com/cgi-bin/stories.pl?ACCT=104&STORY=/www/story/11-28-2006/0004480854&EDATE=
  3. ^ Drug Enforcement Administration, Department of Justice. Schedules of controlled substances: placement of pregabalin into schedule V. Final rule. Fed Regist 2005;70(144):43633-5. PMID 16050051
  4. ^ FDA Approves First Drug for Treating Fibromyalgia. Retrieved on 2007-07-04.
  5. ^ "Pfizer's Lyrica Approved for the Treatment of Generalized Anxiety Disorder (GAD) in Europe". Press release. Retrieved on 2007-07-04.
  6. ^ a b Pfizer Australia Pty Ltd. Lyrica (Australian Approved Product Information). West Ryde: Pfizer; 2006.
  7. ^ Rossi S, editor. Australian Medicines Handbook 2006. Adelaide: Australian Medicines Handbook; 2006. ISBN 0-9757919-2-3

Advanced Search
Included Web Search Engines


Safe Search

close

Top Matching Results

Occasionally Search.com will highlight specialized results that are based on the context of your query. Examples of specialized results include specific links to news, images, or video.

Top Matching Results may highlight information from other Search.com pages, content from the CNET Network of sites, or third party content. The listings are based purely on relevance. Search.com does not receive payment for listings in this section but our partners that provide this data may get paid for listing these products.

Sponsored Links

This section contains paid listings which have been purchased by companies that want to have their sites appear for specific search terms and related content. These listings are administered, sorted and maintained by a third party and are not endorsed by Search.com.

Search Results

Search.com sends your search query to several search engines at one time and integrates the results into one list which has been sorted by relevance using Search.com's proprietary algorithm. You can customize the list of search engines included in your metasearch from the preferences.

The search engines that are used in your metasearch may allow companies to pay to have their Web sites included within the results. To view the Paid Inclusion policy for a specific search engine, please visit their Web site. Search.com does not accept payment or share revenue with any search engine partner for listings in this section.